Shanghai-based gene editing firm CorrectSequence Therapeutics announced it has received a patent from the United States Patent and Trademark Office (USPTO) for its variant base editing (tBE) system, a technology designed to enhance precision and reduce off-target mutations in gene editing.
Technology Highlights
The tBE system integrates a deoxycytidine deaminase inhibitor (dCDI) and a split TEV protease into the base editing framework. This fusion enables targeted editing efficiency improvements while eliminating off-target mutations, allowing simultaneous, precise edits across multiple sites.
Partnership and Applications
CorrectSequence previously licensed exclusive global rights to the tBE system from ShanghaiTech University, with a focus on developing therapies for beta thalassemia. The technology’s ability to minimize off-target effects positions it as a potential breakthrough in treating genetic disorders.-Fineline Info & Tech
